2024-12-03 - Analysis Report
## Merck & Co Inc (MRK) Stock Report

**1. Performance Comparison & Overview:**

Merck & Co Inc (MRK) is a leading pharmaceutical company.  Over the measured period, MRK's cumulative return (72.32%) significantly underperformed the S&P 500 (VOO) cumulative return (130.05%). The difference is -57.7%, placing it at the 8.8th percentile of its historical relative performance compared to the S&P 500.  This indicates MRK has consistently underperformed the broader market over the analyzed period. The provided alpha consistently shows negative values, further supporting underperformance against the market benchmark.

**2. Recent Price Movement:**

* **Closing Price:** $101.64
* **5-Day Moving Average:** $101.34
* **20-Day Moving Average:** $99.99
* **60-Day Moving Average:** $107.54

The price is slightly above the 20-day moving average, suggesting short-term upward momentum. However, it's below the 60-day and significantly below the 60-day moving average, indicating a potential downward trend in the medium term.  The last market price of 100.71 is close to the closing price and does not indicate a significant price jump or drop.


**3. Technical Indicators & Expected Return:**

* **RSI (46.07):** Suggests the stock is approaching oversold territory, potentially indicating a buying opportunity. However, it's not decisively in oversold territory.

* **PPO (0.84):** A positive PPO suggests bullish momentum.

* **Delta_Previous_Relative_Divergence (NaN):** The lack of data prevents analysis of short-term relative divergence.

* **Expected Return (0.0%):**  The provided 0% expected return relative to the S&P 500 over the long term (2+ years) suggests that, based on the data,  consistent long-term outperformance of the S&P 500 is not anticipated for MRK.


**4. Recent Earnings Analysis:**

The provided earnings data shows some volatility:

* **Revenue:** Shows relatively consistent revenue around $16 billion, with slight quarter-to-quarter fluctuations. There's no clear upward or downward trend evident.

* **EPS:** EPS fluctuates significantly.  There's no discernible pattern or trend in EPS from quarter to quarter.  Comparisons to expectations are not available from the data provided.

* **Overall:**  The data provided does not support concluding whether earnings are exceeding or falling short of expectations.  More data (e.g., analyst estimates) would be needed for a complete assessment.


**5. Financial Information Analysis:**

* **Revenue and Profitability:** Revenue remains relatively stable, hovering around $16 billion. Profit margins are high and generally consistent, though there is a slight decline in the last two quarters.

* **Capital and Profitability:** Equity is increasing, showing growth in the company's net worth. ROE shows volatility, with significant swings between positive and negative values over the reported period. This volatility highlights the risk associated with the company's profitability.


**6. News and Recent Issues:**

No news or recent market outlook information is provided to analyze.  Analyst opinions and performance highlights are missing.


**7. Overall Analysis:**

MRK has underperformed the S&P 500 over the analyzed period, showing consistent negative alpha. While recent technical indicators (RSI and PPO) hint at potential short-term buying opportunities,  the low expected return and volatility in both earnings and ROE raise concerns about long-term outperformance compared to the broader market.  Revenue is relatively stable but EPS is highly volatile.  The lack of recent news and analyst data prevents a comprehensive assessment of current market sentiment and future prospects.  Further investigation into analyst estimates, market forecasts, and recent news would be essential for a more complete and nuanced investment decision.


**8. Disclaimer:** This report is based solely on the data provided. It does not constitute financial advice.  Investing involves risk, and past performance is not indicative of future results.  Consult with a financial advisor before making any investment decisions.
